Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (117)	11/18/2002 11:52:11 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ALXN Was up 36.52% on nice volume of 2,973,723 (about 20x its daily average)after it released the results of the COMMA and COMPLY trials and the fact that it is developing pexelizumab with Procter & Gamble Pharmaceuticals.<g> The COMMA trial, which is the one in which patients with an AMI had an early PTCA, the trial did not reach its primary endpoint of infarct size reduction at 72 hours. but it showed a dose-dependent 70% reduction in mortality at 90 days and a 57% reduction in mortality at 180 days. In the COMPLY trial,of 920 patients with an AMI received thrombolytics and although pexelizumab appeared to be well tolerated,there was no reduction in mortality at 90 days. However,a prespecified analysis of the "pooled COMMA and North American COMPLY population"<g>,showed that in this population,the drug was associated with a 55% reduction in 90 day mortality. The stock still has to close above its July 31 intra-day H of 15.95 siliconinvestor.com The PSML data on ALXN today: 15.14 12.10 10.99 & 11.34 (The L is still above.<g>)It had a negative MF of 256,800. Its RSI was up to 86 from the 67 on Friday and the MT improved to +0.36 from -1.32 And it is still way below its March 22 H of 26.69 siliconinvestor.com Bernard